Supply of products by Aspen Pharmacare Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to provide for the regulation of therapeutic goods in Australia. It was introduced to address the need for a comprehensive legislative framework that ensures the safety, efficacy, and quality of therapeutic goods available to the public. The Act aims to protect public health by controlling the importation, supply, and advertising of therapeutic goods. The Therapeutic Goods Administration (TGA), under the auspices of the Australian Government's Department of Health, is the body responsible for administering the Act. The policy objective of the Act is to ensure that therapeutic goods meet necessary standards and are appropriately regulated to safeguard the health and safety of consumers. The 2013 Gazette notice concerning Section 14 and 14A of the Act relates to the supply of specific pharmaceutical products, namely darifenacin hydrobromide, under modified conditions due to a change in sponsorship from Novartis Pharmaceuticals Australia Pty Ltd to Aspen Pharmacare Australia Pty Ltd, with the consent of the Secretary being conditional on certain terms and limited to a specified period.

Scope and Application

The Therapeutic Goods Act 1989, specifically in relation to sections 14 and 14A, governs the supply of therapeutic goods in Australia and provides a framework for the regulation of these products. This legislation applies to entities involved in the supply of therapeutic goods, including pharmaceutical companies like Aspen Pharmacare Australia Pty Ltd, and is administered by the Department of Health and Ageing. The Act's reach is national, ensuring that all therapeutic goods supplied across Australia meet specific regulatory standards. In this instance, the Act facilitated the transition of sponsorship for the supply of certain products from Novartis Pharmaceuticals Australia Pty Ltd to Aspen Pharmacare Australia Pty Ltd, ensuring compliance with labelling requirements as stipulated in Therapeutic Goods Order (TGO) 69. The consent granted to Aspen Pharmacare Australia Pty Ltd is conditional and time-limited, extending until March 31, 2014, with the stipulation that the labels used must reflect the previous sponsor's details, those of Novartis Pharmaceuticals Australia Pty Ltd, and that no other changes have been made to the specified products. Additionally, it mandates arrangements for the effective handling of queries and complaints related to the products.

Key Provisions

The Therapeutic Goods Act 1989 (the "Act") contains various provisions that regulate the supply of therapeutic goods in Australia. Sections 14 and 14A of the Act specifically deal with the consent for supply of therapeutic goods that do not conform with standards set out in Therapeutic Goods Orders (TGOs). In this case, on May 31, 2013, the delegate of the Secretary of the Department of Health and Ageing gave consent (sections 14 and 14A) for Aspen Pharmacare Australia Pty Ltd to supply two specific products, darifenacin (as hydrobromide) (ENABLEX) 7.5 mg and 15 mg modified release tablet blister packs, despite these products not conforming to paragraph 3(2)(l) of TGO 69 because the labels still contained the details of the previous sponsor, Novartis Pharmaceuticals Australia Pty Ltd, instead of the new sponsor, Aspen Pharmacare Australia Pty Ltd. The consent given under section 15(1) of the Act is subject to certain conditions. Firstly, the consent applies only until March 31, 2014. Secondly, the consent pertains to the use of labels previously approved for the old sponsor, Novartis Pharmaceuticals Australia Pty Ltd, which include the sponsor's name and address. Importantly, no other changes have been made to the products themselves. In terms of obligations and requirements, the Act imposes specific duties on the parties involved. Aspen Pharmacare Australia Pty Ltd must ensure that any queries or complaints about the products are promptly referred to the new sponsor. This requirement is facilitated by arrangements made with the previous sponsor, Novartis Pharmaceuticals Australia Pty Ltd, to ensure smooth communication and resolution of any issues that may arise. Failure to comply with the provisions of the Act can result in various consequences. While the specific offences and penalties are not detailed in the provided text, generally under the Act, breaches can lead to both civil and criminal penalties. Civil penalties might include fines, while criminal penalties could involve imprisonment, depending on the severity and nature of the breach. It is important for entities like Aspen Pharmacare Australia Pty Ltd to adhere strictly to the conditions set out to avoid these potential legal repercussions.